Jan 31, 2022 4:01pm EST Ensysce Biosciences Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communication Program
Jan 10, 2022 8:00am EST Ensysce Biosciences Announces First Cohort Dosing in Bioequivalence (BE) Study of Novel “TAAP” Opioid
Jan 05, 2022 4:05pm EST Ensysce Biosciences Announces Participation in the H.C. Wainwright BIOCONNECT Conference
Jan 04, 2022 8:00am EST Ensysce Biosciences Achieves Successful Completion of Part A of Multiple-Ascending Dose (MAD)/Bioequivalents (BE) Trial for its Next Generation Opioid, PF614
Dec 15, 2021 4:05pm EST Ensysce Biosciences Announces First Patients Enrolled in Phase 1 Study of PF614-MPAR™, its unique technology platform to provide opioid overdose protection
Nov 30, 2021 8:00am EST Ensysce Biosciences Announces Clinical Trial Progress of its New Class of Opioids
Nov 15, 2021 5:32pm EST Ensysce Biosciences Reports Third Quarter 2021 Financial Results and Recent Corporate Updates
Nov 08, 2021 8:00am EST Ensysce Biosciences Announces Completion of $15 Million Convertible Note Financing